OliX PharmaceuticalsInc Asset Resilience Ratio
OliX PharmaceuticalsInc asset resilience ratio. OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 37.46% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 226950 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of OliX PharmaceuticalsInc (2016–2025)
Asset resilience ratio of OliX PharmaceuticalsInc from 2016 to 2025. This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. Read 226950 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of OliX PharmaceuticalsInc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩102.67 Billion | 37.46% |
| Total Liquid Assets | ₩102.67 Billion | 37.46% |
Asset Resilience Insights
- Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 37.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio
Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Disc Medicine Inc.
NASDAQ:IRON |
Biotechnology | 84.22% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
OliX PharmaceuticalsInc Asset Resilience Ratio by Year (2016–2025)
OliX PharmaceuticalsInc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.57% | ₩126.15 Billion ≈ $85.49 Million |
₩195.37 Billion ≈ $132.40 Million |
+52.61pp |
| 2024-12-31 | 11.96% | ₩8.52 Billion ≈ $5.78 Million |
₩71.25 Billion ≈ $48.28 Million |
-1.59pp |
| 2023-12-31 | 13.55% | ₩13.93 Billion ≈ $9.44 Million |
₩102.83 Billion ≈ $69.68 Million |
-33.09pp |
| 2022-12-31 | 46.64% | ₩61.87 Billion ≈ $41.93 Million |
₩132.65 Billion ≈ $89.90 Million |
-10.77pp |
| 2021-12-31 | 57.41% | ₩49.76 Billion ≈ $33.72 Million |
₩86.67 Billion ≈ $58.74 Million |
-29.27pp |
| 2020-12-31 | 86.68% | ₩68.11 Billion ≈ $46.16 Million |
₩78.58 Billion ≈ $53.25 Million |
+42.54pp |
| 2019-12-31 | 44.14% | ₩19.95 Billion ≈ $13.52 Million |
₩45.21 Billion ≈ $30.64 Million |
-7.65pp |
| 2018-12-31 | 51.79% | ₩28.81 Billion ≈ $19.53 Million |
₩55.64 Billion ≈ $37.70 Million |
-0.51pp |
| 2017-12-31 | 52.30% | ₩11.32 Billion ≈ $7.67 Million |
₩21.64 Billion ≈ $14.67 Million |
-10.30pp |
| 2016-12-31 | 62.60% | ₩9.48 Billion ≈ $6.43 Million |
₩15.15 Billion ≈ $10.27 Million |
-- |
About OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more